Pioneer Group has reinvested in Nottingham-based company NuVision to help accelerate its first two products – designed to aid the healing of eye conditions – before a Series A round in the next 12 months.
Ariya J Shutterstock
1398011237
reinvestment concept
NuVision’s wound dressings are manufactured from the amniotic membrane, the sac that surrounds babies in the womb, and are used to aid the regeneration and healing of the eye’s surface. Its first product, Omnigen, is already approved for treatment on the NHS and is used in hospitals and private clinics in the UK and overseas.
Omnigen may be applied in the operating theatre or, when used in combination with the company’s bespoke bandage contact lens, OmniLenz, in the outpatient department or clinic.
Andy Hill, CEO of NuVision, said: “We are delighted to receive further support from our existing investors. This investment round is an endorsement of our innovative new therapies for ocular care and our commitment to developing rapid and accessible treatment for ocular injury. The next stage of development is the scaling of our commercial and operational capabilities ahead of a planned Series A round in late 2023 or early 2024.”
